Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clovis Oncology Inc CLVSQ

Healthcare Biotechnology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications... see more

Recent & Breaking News (PINL:CLVSQ)

The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher

Benzinga.com  August 5, 2016

Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8

Business Wire July 26, 2016

12 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  June 29, 2016

Benzinga's Volume Movers

Benzinga.com  June 29, 2016

7 Stocks Moving In Thursday's After-Hours Session: Oracle, Smith & Wesson And More

Benzinga.com  June 16, 2016

8 Biggest Mid-Day Losers For Friday

Benzinga.com  June 10, 2016

How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen

PR Newswire June 9, 2016

Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting

Business Wire June 6, 2016

Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting

Business Wire May 19, 2016

The Shuman Law Firm Investigates Clovis Oncology, Inc.

Business Wire May 11, 2016

Clovis Oncology Announces Q1 2016 Operating Results and Corporate Update

Business Wire May 5, 2016

Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5

Business Wire April 26, 2016

Market Exclusive Research Weekly Biotech Report

Accesswire April 18, 2016

Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Business Wire April 12, 2016

Trading of Clovis Oncology, Inc. Common Stock Halted

Business Wire April 12, 2016

Weekly Biotech Report Covering Opko Health Inc (NYSE:OPK) Intercept Pharmaceuticals (NASDAQ:ICPT) Gilead Sciences, Inc (NASDAQ:GILD) Clovis Oncology, Inc. (NASDAQ:CLVS) Chiasma, Inc. (NASDAQ:CHMA)

Accesswire April 11, 2016

FDA Posts Briefing Documents for Advisory Committee Meeting to Review Clovis Oncology's Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Business Wire April 8, 2016

Clovis Oncology Announces 2015 Operating Results

Business Wire February 25, 2016

Clovis Oncology to Announce Fourth Quarter/Year-End 2015 Financial Results and Host Webcast Conference Call on February 25

Press Releases February 16, 2016

Clovis Oncology Announces Rociletinib New Drug Application Scheduled for Presentation at Upcoming FDA Oncologic Drugs Advisory Committee Meeting

Business Wire February 12, 2016